You have successfully completed the newsletter registration.
We are pleased to welcome you in our mailing list!
Best regards
Your MetrioPharm Blog team
MetrioPharm AG
Bleicherweg 45
CH-8002 Zurich
Newsletter subscription completed
Contact
Eva Brysch
Head of Investor Relations & Corporate Communications
invest@metriopharm.com
Ralf Haubert
Marketing Manager
blog@metriopharm.com
- 08.12.2022 MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients
- 12.10.2022 MetrioPharm Starts Preclinical Experiments in Duchenne Muscular Dystrophy (DMD)
- 29.07.2022 Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19
- 02.03.2022 MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19